Chiltern picks up an Asian CRO with eyes on oncology

CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.

The North Carolina company has paid an undisclosed sum for Pacific Clinical Research, a pan-Asian outfit that specializes in oncology and anti-infective R&D. Through the deal, Chiltern adds direct capabilities in Hong Kong, Korea, Malaysia, the Philippines and Thailand, bolstering its existing presence in the region.

Under the agreement, Pacific Clinical Research founders Robert Teoh and Vonny Iskandar will join Chiltern's management team, building off of years of collaboration between the two companies, Chiltern CEO James Esinhart said.

For Chiltern, the acquisition follows a July buyout of Ockham, an oncology-focused CRO. That deal led the company to reform its operations, with Chiltern Oncology hosting the former Ockham, Chiltern Biopharmaceutics housing its multiphase development and Chiltern Source offering transactional research through a functional service provider model.

The company's latest deal expands that mission, furthering its commitment to cancer R&D and stretching out its presence in Asia Pacific, which included outposts in India, Australia, Singapore and Taiwan.

Since its foundation in 1982, Chiltern has grown to employ about 2,200 people in more than 45 countries, the company said.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.